Think | Create | Scale
Follow
  • Startup Pulse
    altM raises $10.3 million in a Series A round led by Rainmatter by Zerodha and Mela Ventures, with Omnivore, Theia Ventures, Aureolis Ventures, Spectrum Impact and strategic angel investors participating. Venomics AI raises $2.7 million in a pre-seed round co-led by Speciale Invest and South Park Commons, with Operators Studio participating. EloElo Group raises $80 million in a Series C round led by Hornbill Capital and NBCUniversal, with MIT Investment Co. and existing investors participating. Peppermint Robotics raises ₹100 crore (approximately $10.5 million) in a Pre-Series B round led by pi Ventures and Crane Venture Partners, with Asiana Fund participating. O-Health raises an undisclosed amount of funding from Sangita Reddy, BugleRock Capital, Perpetual Capital, Ankit Nagori and Varun Dua. Traversal raises $120 million in a Series B round at a $1 billion valuation, led by Kleiner Perkins, Redpoint and Khosla Ventures, with Sequoia Capital, Battery Ventures and Amex Ventures participating. GIVA raises over $100 million in a round led by Multiples Alternate Asset Management. The Croffle Guys raises ₹14 crore in a round led by V3 Ventures, with N.A.N Partners participating. Solgram raises over $1 million in a pre-seed round led by DSG Consumer Partners and Saama Capital, with Kapil Chopra participating. Sachin Tendulkar makes a strategic investment in Metasports Interactive, the company behind Hitwicket. The amount was not disclosed. altM raises $10.3 million in a Series A round led by Rainmatter by Zerodha and Mela Ventures, with Omnivore, Theia Ventures, Aureolis Ventures, Spectrum Impact and strategic angel investors participating. Venomics AI raises $2.7 million in a pre-seed round co-led by Speciale Invest and South Park Commons, with Operators Studio participating. EloElo Group raises $80 million in a Series C round led by Hornbill Capital and NBCUniversal, with MIT Investment Co. and existing investors participating. Peppermint Robotics raises ₹100 crore (approximately $10.5 million) in a Pre-Series B round led by pi Ventures and Crane Venture Partners, with Asiana Fund participating. O-Health raises an undisclosed amount of funding from Sangita Reddy, BugleRock Capital, Perpetual Capital, Ankit Nagori and Varun Dua. Traversal raises $120 million in a Series B round at a $1 billion valuation, led by Kleiner Perkins, Redpoint and Khosla Ventures, with Sequoia Capital, Battery Ventures and Amex Ventures participating. GIVA raises over $100 million in a round led by Multiples Alternate Asset Management. The Croffle Guys raises ₹14 crore in a round led by V3 Ventures, with N.A.N Partners participating. Solgram raises over $1 million in a pre-seed round led by DSG Consumer Partners and Saama Capital, with Kapil Chopra participating. Sachin Tendulkar makes a strategic investment in Metasports Interactive, the company behind Hitwicket. The amount was not disclosed.

    • Just In

    Emcure Secures Exclusive Distribution Rights for Sanofi India’s Oral Anti-diabetic Drugs

    Latest News Posted on  —by Salil Urunkar

    Share

    Oral Anti-Diabetic Drugs

    Mumbai: Emcure Pharmaceuticals Ltd. has announced an exclusive distribution and promotion partnership with Sanofi India Limited (SIL) for its portfolio of oral anti-diabetic drugs (OADs).

    The agreement, effective immediately, marks a significant step in enhancing healthcare delivery for the country’s growing diabetic population.

    Under the terms of the partnership, Emcure will exclusively promote and distribute Sanofi’s oral anti-diabetic drugs brands, including the widely prescribed Amaryl and Cetapin, throughout India.

    Also Read: Piramal Pharma Solutions Launches USD 90M Expansion to Boost US Manufacturing

    Sanofi will continue to own and manufacture these brands at its facilities in India and globally. There will be no employee transition from Sanofi to Emcure as part of this deal.

    “Over 100 million Indians are currently living with type 2 diabetes, with more than 60% struggling to manage blood sugar levels,” said Eric Mansion, General Manager – Pharma Southeast Asia and India, Sanofi.

    “This partnership with Emcure – known for its strong pan-India reach – will ensure that our best-in-class oral anti-diabetic drugs reach more patients and doctors, driving better diabetes management outcomes.”

    With diabetes emerging as one of India’s most pressing health challenges, this collaboration is set to improve therapeutic access and adherence, particularly in Tier 2 and Tier 3 cities where Emcure has a robust footprint.

    “We are proud to partner with Sanofi India to expand access to their trusted oral diabetes therapies,” said Satish Mehta, CEO & MD of Emcure Pharmaceuticals.

    “This alliance aligns with our mission to offer comprehensive, high-quality diabetes care and improve health outcomes for millions across India.”

    Also Read: Torrent Pharmaceuticals to Acquire JB Chemicals in INR 25689 Cr Deal from KKR

    Scaling the Impact of Oral Anti-Diabetic Drugs

    The deal strengthens Emcure’s diabetes portfolio and reinforces Sanofi’s focus on scaling the impact of its oral anti-diabetic drugs therapies.

    Together, the companies are positioned to support better diabetes care across India’s vast and underserved regions.

    Author

    • Salil Urunkar

      Salil Urunkar is a senior journalist and the editorial mind behind Sahyadri Startups. With years of experience covering Pune’s entrepreneurial rise, he’s passionate about telling the real stories of founders, disruptors, and game-changers.

    Share

    Related Posts

    Sahyadri Startups
    Copyright © 2026. All rights reserved. Powered by Explore Media Powered by Probewise.
    Back to top